Regeneron, Bayer deal

Regeneron granted Bayer exclusive rights outside the U.S. to a combination that includes Regeneron’s nesvacumab ( REGN910) and its ophthalmic drug Eylea aflibercept ophthalmic solution.

Regeneron will receive $50 million up front and is eligible for up to $80 million in development and regulatory milestones. The companies will share global development costs for the combo and share ex-U.S. profits equally. Regeneron retains exclusive, U.S. commercialization rights and will retain all profits from U.S. sales. ...